SIETES :: 92833 citas

Resultados de la búsqueda por CÁNCER DE TIROIDES REFINAR BÚSQUEDA

1.

Anónimo. FDA approves first oral GLP-1 treatment for type 2 diabetes. FDA 2019:1. [Ref.ID 103193]

2.

Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]

3.

Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, for the EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:28 de septiembre. [Ref.ID 102096]

4.

Anónimo. NICE considers eliminating Sanofi, Ipsen thyroid cancer drugs From Cancer Drug Fund. DIA Daily 2017:2. [Ref.ID 102033]

5.

Mackenzie IS, Morant SV, Wei L, Thompson AM, MacDonald TM. Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. Br J Clin Pharmacol 2017;83:653-63. [Ref.ID 101935]

6.

Ariz MJ, Elizondo G. Nuevos antidiabéticos. ¿Qué lugar deben ocupar en terapéutica?. Boletín de Información Farmacoterapéutica de Navarra 2016;24:1-8. [Ref.ID 101436]

7.

Anónimo. Lenvatinib et cancers différenciés de la thyroïde. Prescrire 2016;36:893-5. [Ref.ID 101004]

8.

Anónimo. Sorafénib et cancers différenciés de la thyroïde. Prescrire 2015;35:731. [Ref.ID 99844]

9.

Anónimo. Cabozantinib. Prescrire 2015;35:650-3. [Ref.ID 99710]

10.

Anónimo. Lenvatinib (Lenvima) for thyroid cancer . Med Lett Drugs Ther 2015;57:120-1. [Ref.ID 99468]

11.

Schumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukaris AG, Kiyota N, Taylor MH, Kim S-B, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radiodiodine-refractory thyroid cancer. N Engl J Med 2015;372:621-30. [Ref.ID 98795]

12.

Anónimo. Thyroid cancer treatment performs well in clinical trial, FDA approval expected. DIA Daily 2014:13 de febrero. [Ref.ID 98776]

13.

Fojo T, Mallankody S, Lo A. Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: The John Conley Lecture. JAMA Otolaryngol Head Neck Surg 2014;149:1-12. [Ref.ID 98016]

14.

Anónimo. Sorafenib (Nexavar) for thyroid cancer. Med Lett Drugs Ther 2014;56:43-4. [Ref.ID 97918]

15.

Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JWA, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger MJ, on behalf of the DECISION Investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384:319-28. [Ref.ID 97831]

16.

Sitges-Serra A. Clinical guidelines at stake. J Epidemiol Community Health 2014;68:906-8. [Ref.ID 97447]

17.

Moses A. Response: Novo Nordisk replies to BMJ investigation on cretins. BMJ 2013;347:25. [Ref.ID 96134]

18.

Cohen D. Incretins and pancreatic cancer. Investigations editor's reply. BMJ 2013;347:25. [Ref.ID 96133]

19.

Barnett AH, O'Hare P. Incretins and pancreatic cancer. Cardiovascular benefits in incretins. BMJ 2013;347:24-5. [Ref.ID 96132]

20.

Holt RIG. Incretins and pancreatic cancer. Only one side of the story. BMJ 2013;347:24. [Ref.ID 96131]